Japan Approves Eisai's Humira, Mitsubishi Tanabe's Remicade In Same-day Approval For Psoriasis
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Tokyo-headquartered Eisai and Osaka-based Mitsubishi Tanabe Pharma Jan. 20 simultaneously received Ministry of Health, Labor and Welfare approval to launch Japan's first fully human biological agents for the additional indication of psoriasis
You may also be interested in...
U.S. FDA Approves Roche/Chugai's Actemra For Second-line RA
Roche Japanese subsidiary Chugai's novel interleukin-6 inhibitor Actemra gained U.S. FDA approval Jan. 8 for treating patients with moderately to severely active rheumatoid arthritis for whom TNF blockers aren't working - a good beginning but still a ways from the first-line indication the pharma sought and still hopes to gain using data from its risk management programs and other sources
Roche's Chugai Licenses Innovative Antibody Technology To Accelerate Drug Discovery
Roche Japan unit Chugai Pharmaceutical Nov. 30 announced a licensing agreement with Tokyo-based new drug discovery firm Biocomber. Chugai will use Biocomber proprietary cell-free protein synthesis technology Puresystem to speed up global antibody drug development
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).